ClinicalTrialsFinder

Refractory High Risk Myelodysplastic Syndrome Clinical Trials in Baltimore, Maryland

1 recruitingBaltimore, Maryland

Showing 1–1 of 1 trials

Recruiting
Phase 2

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center63 enrolled3 locationsNCT03383575